Global Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 684.2 million in 2020 and is expected to exhibit a CAGR of 1.90% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Osteogenesis imperfecta (OI) is a progressive medical condition, which requires life-long management to prevent complications and deformity. The symptoms of osteogenesis imperfecta can vary from person to person. Some people may have no symptoms, while others may suffer multiple fractures throughout their lives. While it may be difficult to differentiate between a case of osteogenesis impractica and another medical condition, a healthcare provider will use their medical knowledge to treat the condition.
For instance, in February 2019, National Institutes of Health (NIH) research wing, The Brittle Bone Disorders Consortium (BBDC), started determining the safety and effectiveness of anti-TGFβ antibody fresolimumab for the treatment of OI condition. Fresolimumab is an antibody, which can silence TGF-β. This antibody protein is important for bone formation and increased TGF-β activity helps in bone strength. In clinical studies in mice with OI, it is noted that silencing TGF-β can increase bone mass, strength, and quality.
To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/4064
Moreover, players are actively engaged in strategic collaborations to expand their market presence and product offerings. For instance, in October 2019, Recombinetics entered into a collaborative agreement for a research project with Mayo Clinic. The company’s aim behind this collaboration was to advance OI research by developing the first-ever swine models of osteogenesis imperfecta. preclinical researchers, with the help of these models, will be able to better understand the progression and etiology of the disorder. This will provide a reliable preclinical model to establish the efficacy and safety of new therapies required for the patients with osteogenesis imperfecta.
Osteogenesis Imperfecta Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has adversely affected the research industry. It has become difficult for the researchers to conduct researches during this COVID-19 pandemic. Therefore, there has been a delay in the completion of clinical trials and hence the launch of new products.
Growing funding for research & development to develop novel treatment and therapies is a key factor augmenting growth of the global osteogenesis imperfecta treatment market. Moreover, the emergence of special drug designations by various regulatory authorities associated to osteogenesis imperfecta is another key factor boosting the market growth. For instance, in November 2017, the Europe Medicines Agency (EMA) expanded all the indications for the first drug setrusumab for osteogenesis imperfect treatment.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4064
Key Takeaways of the Osteogenesis Imperfecta Treatment Market:
- The osteogenesis imperfecta treatment market is expected to exhibit a CAGR of 1.9% during the forecast period (2020-2027), owing to surge in funding for research & development to develop novel therapies and treatments
- Among route of administration, oral segment is expected to hold significant revenue share in the market, due to growing product demand coupled with increasing cases of osteogenesis imperfecta. For instance, according to the Genetics Home Reference (GHR), osteogenesis imperfecta affects around 1 in 10,000 to 20,000 people across the world.
- Major players operating in the osteogenesis imperfecta treatment market include Bone Therapeutics SA, Mereo BioPharma Group plc, Celgene Corporation, Eli Lilly and Company, Cipla Inc., Amgen Inc, Sun Pharmaceutical Industries Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc. Jubilant Life Sciences Ltd., Aurobindo Pharma, and Genzyme Corp.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/4064
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drugs
- Market Snippet, By Route of Administration
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- New Development in Osteogenesis Imperfecta Treatment
- Pipeline Analysis
- Key Developments
- Acquisition, Collaborations & Partnerships
- Epidemiology
- Market Dynamics
- Global Osteogenesis Imperfecta Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
- Pre-COVID situation
- Post-COVID demand
- Need for Osteogenesis Imperfecta Treatment
- Recommendations and Guidelines by Regulatory Bodies
- Global Osteogenesis Imperfecta Treatment Market, By Drugs, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Teriparatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Denosumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Osteogenesis Imperfecta Treatment Market, By Route of Administration, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/osteogenesis-imperfecta-treatment-market-3322
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837